NETs: Protection or Harm in Neonatal Inflammation or Infection
University of Utah · with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · NCT00747851
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Any age listed · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 388
- US sites recruiting
- 1
- Study start
- October 2003
- Record last updated
- December 5, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a prospective in vitro cell biology study of polymorphonuclear leukocyte (PMN) protein synthesis in response to PAF. PMNs from cord blood of premature human infants at risk for NEC (birth weight between 501 - 1500 grams) and PMNs from cord blood of healthy term infants will be isolated and stimulated with PAF, a biologically active phospholipid implicated in the pathogenesis of NEC. NEC, a disease of prematurity with an incidence of 10.1% of infants born weighing between 501 - 1500 grams, is associated with significant morbidity and mortality. We will compare the protein synthesis of inflammatory modulators, including Interleukin 6 Receptor alpha (IL-6R alpha) and Retinoic Acid Receptor alpha (RAR alpha) proteins to protein synthesis responses already observed in PMNs isolated from healthy adults. Furthermore, we will characterize the expression and activity of the mammalian target of rapamycin (mTOR) translational protein synthesis control pathway in PMNs isolated from preterm and term infants and compare those results with previous observations in PMNs isolated from adults. This pathway is known to regulate IL-6R alpha and RAR alpha protein expression in PMNs isolated from adults. We will also follow those premature infants at risk for NEC clinically to determine which infants develop NEC and what risk factors may be associated with NEC in this population.
Conditions: Necrotizing Enterocolitis (NEC)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patients hospitalized in the NICU who were less than or equal to 1500 grams or less than 30 weeks gestational age at birth; Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery; Cord blood isolated within first hour of life; and parents or guardians must have signed informed consent.
Exclusion Criteria
- Infants with major congenital anomalies will be excluded.
Recruiting US locations
University of Utah
Salt Lake City, UT 84112
Site contact: Christian C Yost, M.D. · 801/581-7052 · christian.yost@hmbg.utah.edu
Study contacts (from the official record)
- Christian C Yost, M.D. · 801/581-7052 · christian.yost@hmbg.utah.edu
Similar studies in Utah
All healthy volunteers studies in Utah →- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- South Jordan, UT + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study of LY4088044 in Healthy Participants
Eli Lilly and Company
- Location
- Salt Lake City, UT + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Gilead Sciences
- Location
- Salt Lake City, UT + 2 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Salt Lake City, UT + 5 other US sites
- Eligibility basics
- Ages 18+